Québec City, Canada, October 26, 2010 – Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), today announced that it will make a poster presentation, as well as an oral presentation on preclinical results for AEZS-131, a leading highly selective Erk inhibitor, which support its further evaluation as a potential anticancer compound in monotherapy or in combination with PI3K/Akt pathway inhibitors. Both presentations will be made during the Cambridge Healthtech Institute’s 8th International “Discovery on Target” Conference, to be held November 2-4, 2010, in Boston, Massachusetts.
Poster presentation:
Title: “A highly selective Erk-Inhibitor with anti-proliferative activity and the potential for combination therapy with modulators of the PI3K pathway ", M.Teifel, I. Seipelt,
L. Blumenstein, S. Baasner, G. Mueller, B. Aicher, E. Guenther and M. Gerlach.
Presenter: Michael Teifel, Ph.D., Senior Director - Head of Preclinical Development, Aeterna Zentaris
Poster group: 100
Date: Tuesday, November 2, 2010, through Thursday, November 4, 2010
Location: Exhibit Space, World Trade Center, Boston, MA
Oral presentation:
Title: “A highly selective Erk-Inhibitor with anti-proliferative activity and the potential for combination therapy with modulators of the PI3K pathway “
Presenter: Michael Teifel, Ph.D., Senior Director - Head of Preclinical Development, Aeterna Zentaris
Oral Presentation Track: ”The Challenge of Developing Kinase Inhibitors”
Date: Thursday, November 4, 2010, at 11:25 a.m. (Eastern Time)
Location: World Trade Center, Boston, MA
About Aeterna Zentaris Inc.
Aeterna Zentaris is a late-stage oncology drug development company currently investigating potential treatments for various cancers including colorectal, ovarian, and endometrial cancer as well as multiple myeloma. The Company’s innovative approach of “personalized medicine” means tailoring treatments to a patient’s specific condition and to unmet medical needs. Aeterna Zentaris’ deep pipeline is drawn from its proprietary discovery unit providing the Company with constant and long-term access to state-of-the-art therapeutic options. For more information please visit www.aezsinc.com.
Investor Relations Ginette Vallières Investor Relations Coordinator (418) 652-8525 ext. 265 gvallieres@aezsinc.com
Media Relations Paul Burroughs Director of Communications (418) 652-8525 ext. 406 pburroughs@aezsinc.com
